Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations-Reference-Cited by-同舟云学术

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Published:2018-12 Issue:1 Volume:6 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Karzai Fatima,VanderWeele David,Madan Ravi A.,Owens Helen,Cordes Lisa M.,Hankin Amy,Couvillon Anna,Nichols Erin,Bilusic Marijo,Beshiri Michael L.,Kelly Kathleen,Krishnasamy Venkatesh,Lee Sunmin,Lee Min-Jung,Yuno Akira,Trepel Jane B.,Merino Maria J.,Dittamore Ryan,Marté Jennifer,Donahue Renee N.,Schlom Jeffrey,Killian Keith J.,Meltzer Paul S.,Steinberg Seth M.,Gulley James L.,Lee Jung-Min,Dahut William L.

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-018-0463-2.pdf

Reference46 articles.

1. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–12.

2. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of Ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate Cancer. J Clin Oncol. 2017;35(1):40–7.

3. Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, et al. PD-L1 is highly expressed in enzalutamide resistant prostate cancer. Oncotarget. 2015;6(1):234–42.

4. Graff JN, Alumkal JJ, Thompson R, Moran A, Thomas G, Wood M, et al. Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): extended follow up. J Clin Oncol. 2018;36(suppl):abstr 5047.

5. Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22(4):813–20.

Cited by 229 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microsatellite Instability-High and High Tumor Mutation Burden Frequencies in Urologic Malignancies Off-Label for Immune Checkpoint Inhibitors in Japan: A Retrospective Single-Institutional Cohort;Cureus;2024-09-13

2. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors;Journal of Clinical Oncology;2024-09-01

3. Increased circulating polymorphonuclear myeloid-derived suppressor cells are associated with prognosis of metastatic castration-resistant prostate cancer;Frontiers in Immunology;2024-06-03

4. Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer;Journal of Thoracic Disease;2024-06

5. Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors;Biomedicine & Pharmacotherapy;2024-06